Cargando…
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
INTRODUCTION: No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. METHOD: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ...
Autores principales: | Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., Toko, L., Mezher, C., Kadiane-Oussou, N.J., Bossert, M., Bozgan, A.-M., Charpentier, A., Roux, M.-F., Contreras, R., Mazurier, I., Dussert, P., Gendrin, V., Conrozier, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202806/ https://www.ncbi.nlm.nih.gov/pubmed/32387320 http://dx.doi.org/10.1016/j.medmal.2020.05.001 |
Ejemplares similares
-
Pneumopathies graves liées au COVID-19 : facteurs prédictifs de mortalité après traitement par tocilizumab
por: Kadiane-Oussou, N., et al.
Publicado: (2020) -
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)
por: Lohse, Anne, et al.
Publicado: (2020) -
Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab’s Place in COVID-19 Pneumonia
por: Klopfenstein, Timothée, et al.
Publicado: (2021) -
Cohorte de 206 patients avec pneumopathie à SARS-CoV-2 : le tocilizumab diminue la mortalité et/ou le recours à la ventilation mécanique invasive
por: Klopfenstein, T., et al.
Publicado: (2020) -
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
por: Klopfenstein, Timothée, et al.
Publicado: (2020)